Everlasting and Zomato founder Deepinder Goyal’s wearable startup Temple is buying London-based longevity drugs apply Longevous for an undisclosed quantity, including medical and scientific experience forward of the launch of its machine.

Longevous founders Robert Mohr and Avi Roy, together with their staff, will be part of Temple full-time, Goyal mentioned in a submit on X. Mohr will grow to be chief medical officer, whereas Roy will function head of science.

Temple acquires London-based Longevous

Hi there everybody, fast replace on @temple

We’re excited to share that Temple is buying Longevous, an evidence-based longevity drugs apply based mostly in London. The founders, Rob and Avi, and their staff are becoming a member of Temple full time. They…

— Deepinder Goyal (@deepigoyal) August 27, 2026

“We’re excited to share that Temple is buying Longevous, an evidence-based longevity drugs apply based mostly in London,” Goyal mentioned.

“The founders, Rob and Avi, and their staff are becoming a member of Temple full time. They create in deep medical experience and publication expertise to work alongside our in-house science staff as we put together for launch,” he added.

Mohr is a board-certified doctor with practically twenty years of medical expertise, together with work in emergency drugs, and has moved into longevity drugs. Roy is an Oxford-trained biomedical scientist whose work has spanned longevity analysis and enterprise.

Longevous will proceed to function as a part of Temple, with Mohr and Roy persevering with to take care of its purchasers, based on Goyal.

Goyal mentioned the deal developed from an opportunity assembly with the 2 founders at a dinner in London a number of months in the past.

“A few months in the past, I met Rob and Avi at a dinner occasion in London I had nearly skipped. I’m very glad I didn’t,” he mentioned.

Goyal mentioned the pair observed the Temple machine he was sporting on the facet of his brow, prompting a dialogue in regards to the science behind the wearable.

“By the tip of our final course, they requested me if they might attempt Temple for themselves,” he mentioned.

Mohr and Roy then wore the machine for about two months whereas going about their day by day actions and have become concerned with Temple’s science staff.

In line with Goyal, they examined the corporate’s proprietary “Entropy” metric, examined information collected by the machine and challenged a number of the assumptions behind its growth. Additionally they reviewed Temple’s first scientific manuscripts earlier than submission.

Temple is creating a wearable that attaches to the facet of the brow, across the temple, moderately than being worn on the wrist.

The corporate mentioned the place permits the machine to gather alerts associated to cerebral blood movement, oxygenation and coronary heart fee, and to observe modifications related to actions together with train, sleep, restoration and meditation.

On the centre of the product is a proprietary measure referred to as Entropy, which Temple describes as an indicator of metabolic and sympathetic demand on the physique.

Goyal has mentioned the Entropy rating updates each second on a scale of 1 to 250, with decrease readings related to deeper relaxation and better readings with larger bodily exertion.

Temple’s claims in regards to the machine and its proprietary measurements are nonetheless being developed and evaluated. The corporate states in its phrases of use that Temple just isn’t a medical machine and isn’t supposed to diagnose, deal with, treatment or stop medical circumstances. It additionally mentioned info from the machine is meant for normal wellness and informational functions.

Goyal mentioned on 21 August that Temple would quickly start taking pre-orders for a restricted launch version of the wearable, with shipments anticipated earlier than the tip of 2026. He mentioned the newest model is lower than half the scale of the model beforehand proven.

The Financial Occasions reported in July that Temple was anticipated to cost its debut wearable at Rs 75,000-80,000, concentrating on premium shoppers. The indicative worth would come with lifetime entry to Temple’s software program platform and a lifetime provide of adhesive tapes used to connect the machine.

The report additionally mentioned Temple was getting ready for an additional funding spherical at a valuation of about $500 million.

Temple raised $54 million in its first funding spherical in February at a post-money valuation of about $190 million. Traders included Peak XV Companions, Steadview Capital, Dharana Capital and Information Edge Ventures, alongside greater than 80 particular person buyers.